| |
Axelar AB is a Swedish biotechnology company that focuses
its activities on research related to the insulin-like growth
factor-1 (IGF-1) receptor inhibitors and their applications
in important human diseases, especially cancer.
Axelar’s overall objective is to develop innovative
small-molecule compounds that inhibit the IGF-1 receptor for
treatment of IGF-1 receptor-dependent diseases where a significant
unmet medical need still exists.
Axelar has successfully completed its first Phase I/II clinical
study in advanced-stage cancer patients with solid tumors.
Axelar is planning to start a randomized Phase II program
in patients suffering from non-small cell lung carinoma. |
|
Latest news
Press release December 28, 2011
Axelar initiates a Phase II clinical study with AXL1717
for the treatment of non-small cell lung cancer
READ
MORE
New poster presented at the European
Multidisciplinary Cancer Congress September 26, 2011
Phase I Dose-escalation Study of AXL1717: a Novel Targeted
Oral Insulin-like Growth Factor-1 Receptor (IGF-1R) Inhibitor
and Its Implications for Patients with Non-small Cell Lung
Carcinoma
READ
MORE
Press release September 26, 2011
Axelar reports good safety profile of AXL1717 in Phase
I/II in cancer patients
READ
MORE
Press release July 07, 2011
Axelar reports completion of the Phase I/II safety
study with AXL1717 in cancer patients
READ
MORE
See also News
|
|
